Journal Article Epublish 1 citation
PubMed: 40188066 DOI: 10.1186/s13065-025-01459-5
Synthesis of thiazoloquinolinone derivatives: molecular docking, MD simulation, and pharmacological evaluation as VEGFR-2 inhibitors.
BMC Chem 19(1):90
Authors: Zeinab Amiri, Mohammad Bayat, Davood Gheidari
Affiliations
- Department of Chemistry, Faculty of Science, Imam Khomeini International University, Qazvin, Iran.
- Department of Chemistry, Faculty of Science, Imam Khomeini International University, Qazvin, Iran.
- Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran.
Abstract
We synthesized a series of novel thiazoloquinolinone derivatives, achieving moderate to high yields ranging from 74 to 96%, and assessed their efficacy against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) using in silico methodologies. The structures of these compounds were characterized through various spectroscopic techniques, including H-NMR, C-NMR, IR, and mass spectrometry. Comprehensive computational analyses, encompassing molecular docking, molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling, were conducted. Docking studies with VEGFR-2 revealed that all synthesized compounds exhibited docking scores between -Â 3.24 and -Â 6.63, indicating varying degrees of binding affinity. Notably, compound (5e) demonstrated the strongest binding affinity with an energy of -Â 6.63Â kcal/mol. The MD simulations indicated that Lys868 was one of the amino acids exhibiting the highest frequency of interaction throughout the simulation. Analysis of the ADMET and physicochemical properties revealed that all inhibitor compounds possess favorable pharmacological characteristics.
MeSH
Vascular Endothelial Growth Factor Receptor-2
Cited by
- Synthesis, cytotoxic activity, molecular docking, molecular dynamics simulations, and ADMET studies of novel spiropyrazoline oxindoles based on domino Knoevenagel-Michael cyclization as potent non-toxic anticancer agents targeting β-tubulin and EGFR, with anti-MRSA activity. RSC Adv, 2025
- Computational studies on structural aspects of pyrazolo[3,4-b]pyridine derivatives as TRKA inhibitors in cancer therapy. Sci Rep, 2025